1-5 of 5
Matilde Follo
Close
Sort by
Journal Articles

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Annalisa Astolfi, PhD, Domenico Russo, MD, Marco Gobbi, MD, Costanza Bosi, MD, Monica Crugnola, MD, Marta Stanzani, MD, Stefano Ratti, MD, Sarah Parisi, MD, Marilena Barraco, PhD, Lucia Manzoli, MD, Andrea Pession, MD, Lucio Cocco, MD, PhD, Carlo Finelli, MD
Journal: Blood
Blood (2016) 128 (22): 5091.
https://doi.org/10.1182/blood.V128.22.5091.5091
Published: 2016
Journal Articles

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Carlo Finelli, MD, Cristina Clissa, MD, Matilde Follo, PhD, Marta Stanzani, MD, Sarah Parisi, MD, Sara Mongiorgi, PhD, Marilena Barraco, PhD, Paolo Avanzini, MD, Costanza Bosi, MD, Barbara Castagnari, MD, Anna Candoni, MD, Monica Crugnola, MD, Maria Benedetta Giannini, MD, Marco Gobbi, MD, Giovanna Leonardi, Gian Matteo Rigolin, Domenico Russo, MD, Patrizia Tosi, Giuseppe Visani, MD, Lucio Cocco, MD, PhD, Michele Cavo, MD
Journal: Blood
Blood (2016) 128 (22): 3169.
https://doi.org/10.1182/blood.V128.22.3169.3169
Published: 2016
Journal Articles

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Carlo Finelli, MD, Cristina Clissa, MD, Matilde Follo, PhD, Marta Stanzani, MD, Sarah Parisi, MD, Sara Mongiorgi, PhD, Paolo Avanzini, MD, Costanza Bosi, MD, Barbara Castagnari, MD, Anna Candoni, MD, Monica Crugnola, MD, Maria Benedetta Giannini, MD, Marco Gobbi, MD, Giovanna Leonardi, Gian Matteo Rigolin, Domenico Russo, Patrizia Tosi, Giuseppe Visani, MD, Lucio Cocco, MD, PhD, Michele Cavo
Journal: Blood
Blood (2015) 126 (23): 2871.
https://doi.org/10.1182/blood.V126.23.2871.2871
Published: 2015
Journal Articles

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Carla Filì, MD, Carlo Finelli, MD, Marco Gobbi, MD, Giovanni Martinelli, MD, Ilaria Iacobucci, MD, Emanuela Ottaviani, MD, Lucio Cocco, MD, Matilde Follo, MD, Anna Candoni, Erika Simeone, Maurizio Miglino, MD, Francesco Lauria, MD, Monica Bocchia, MD, Marzia Defina, MD, Cristina Clissa, MD, Francesco Lanza, Antonio Curti, MD, Stefania Paolini, MD, PierAngelo Spedini, Cristina Skert, MD, Cesare Bergonzi, MD, Michele Malagola, MD, Annalisa Peli, MD, Alessandro Turra, MD, Federica Cattina, MD, Chiara Colombi, Domenico Russo, MD
Journal: Blood
Blood (2010) 116 (21): 4029.
https://doi.org/10.1182/blood.V116.21.4029.4029
Published: 2010
Journal Articles

FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.

Tiziana Grafone, Michela Palmisano, Emanuela Ottaviani, Alberto Maria Martelli, Alessandra Cappellini, Matilde Follo, Nicoletta Testoni, Stefania Paolini, Michele Baccarani, Giovanni Martinelli
Journal: Blood
Blood (2006) 108 (11): 2308.
https://doi.org/10.1182/blood.V108.11.2308.2308
Published: 2006